Astellas Pharma Inc 2017 AR2
The report highlights Astellas Pharma Inc.'s financial and non-financial performance for the fiscal year ended March 31, 2017. Key achievements include the steady growth of mainstay products such as XTANDI and the overactive bladder franchise, alongside strategic acquisitions like Ganymed Pharmaceuticals AG to strengthen the oncology pipeline. On the sustainability front, the company reduced its greenhouse gas emissions to 179 kilotons and improved its water resources productivity. Additionally, Astellas expanded its social impact through initiatives like the Action on Fistula program in Kenya and the launch of the Astellas Emerging Countries Empowerment Program.
Company: Astellas Pharma Inc
Sector: Manufacturing
Country: Japan
Year: 2017
Type: AR2
Pages: 160
Back to company
Astellas Pharma Inc
Annual Report
The report highlights Astellas Pharma Inc.'s financial and non-financial performance for the fiscal year ended March 31, 2017. Key achievements include the steady growth of mainstay products such as XTANDI and the overactive bladder franchise, alongside strategic acquisitions like Ganymed Pharmaceuticals AG to strengthen the oncology pipeline. On the sustainability front, the company reduced its greenhouse gas emissions to 179 kilotons and improved its water resources productivity. Additionally, Astellas expanded its social impact through initiatives like the Action on Fistula program in Kenya and the launch of the Astellas Emerging Countries Empowerment Program.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2017
Reporting Period
Apr 1, 2016 - Mar 31, 2017
Fiscal Year
2016
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental: AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Energy Consumption
Water Consumption
Women in Management
Employees